Table 2.

Summary of Major Cell-Based / Cytokine Clinical Trials

Study	Method of delivery	Patients treated/ control	Placebo/ control	Cell type Cell number or Dose	Time of cell delivery (days post-MI)	Results	Reference
Strauer	Intracoronary	10/10 30 (CPC)	control	BM-MNC 9 × 106 to 2.8 × 107 CPC	7	Improved contractility and reduced infarct size	Strauer et al 2002 110
TOPCARE-AMI	Intracoronary	29 (BM-MNC)	N/A	1.3 × 107 BM-MNC 2.4 × 108	3 to 7	Improved EF and reduced infarct size	Assmus et al 2002 111 Britten et al 2003 112 Schachinger et al 2004 113
BOOST	Intracoronary	30/30	control	BM-MNC 24 × 109	6	Improved EF at 6 months No difference at 18 months	Wollert et al 2004 100 Meyer et al 2006 101
Janssens	Intracoronary	33/34	placebo	BM-MNC 3.0 × 108 cells	1	No effect	Janssens et al 2006 114
Chen	Intracoronary	34/35	placebo	MSC 48 × 1010 to 60 × 1010	18	Improved and perfusion at 3 months	Chen et al 2004 115
REPAIR-AMI	Intracoronary	102/102	placebo	BM-MNC 2.4 × 108	4	Improved EF and reduced infarct size at 4 months	Schachinger et al 2006 103
ASTAMI	Intracoronary	100	control	BM-MNC 8.7 × 107	5 to 8	No difference at 6 months	Lunde et al 2006 102
FIRSTLINE-AMI	Mobilization	25/25	control	G-CSF 10μg/Kg BW	0 to 6 1QD	Improved EF and remodeling at 4 months	Ince et al. 2005 104
STEMMI	Mobilization	39/39	placebo	G-CSF 10μg/Kg BW	0 to 6 1QD	No difference at 6 months	Ripa et al 2006 106
REVIVAL II	Mobilization	56/58	placebo	G-CSF 10μg/Kg BW	0 to 5 1QD	No difference at 6 months	Zohlnhoefer et al 2006 105

BM-MNC: unfractionated bone marrow mononuclear cells; CPC: Circulating progenitor cells; MSC: mesenchymal stem cells; 1QD: one subcutaneous G-CSF injection per day; EF: left ventricular ejection fraction.